Cardiologists and vascular surgeons were previously told they could still use the device if necessary. Now, however, the message is that they should return the product to the manufacturer.

Back in June, CMS proposed significant updates to its current TAVR policies. Three leading healthcare societies have now joined forces to share their own perspective on the potential updates. 

When patients take semaglutide, you can't necessarily predict the cardiovascular impact by tracking weight loss. A lot of it appears to comes down to the dose. 

Enlicitide, the new oral PCSK9 inhibitor from Merck, will be sold under the brand name Lipfendra. It is approved to reduce LDL-C in patients with hypercholesterolemia, including HeFH.

Many heart patients who would benefit from TAVR are still missing out on the care they need. AI, it turns out, can help cardiologists find those patients. An upcoming webinar is set to explore this topic at length.

Trace amounts of blood were identified within the sealed packaging of these devices. No patients were exposed to the foreign material, and no adverse events were reported, but Medtronic is recalling the devices as a precaution.

The deal, first announced in April, includes an upfront payment of $20 million and up to an additional $25 million based on certain milestones.

AI impacts care in so many ways now that it often goes unnoticed by clinicians. 

Specific lots of several procedure kits have been recalled after the FDA identified quality issues during a recent inspection.

Philippe Généreux, MD, presented updated findings from one of cardiology's most closely watched trials at New York Valves 2026. 

The technique analyzes standard pre-contrast cardiac MRIs to produce “virtual contrast” images resembling enhanced ones.  

From the right come heated calls for reform if not outright overhaul of the 340B Drug Pricing Program. From the left, vociferous insistence on letting 340B be, albeit with modest tweaks and fixes. From hospitals and drug manufacturers: finger-pointing.